New drug cocktail takes on advanced lung cancer in first human trial
NCT ID NCT07229599
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called MHB036C combined with other anti-cancer medicines in 300 people with advanced lung cancer. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have tried standard treatments without success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MHB036C (an experimental drug) combined with MHB039A, furmonertinib, or carboplatin
What this could lead to
If it works, this could point toward a new treatment option for advanced lung cancer patients who have run out of standard therapies.
What could go wrong
This is an early first-in-human trial, so safety and effectiveness are not yet known. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••